Amgen (NASDAQ:AMGN) has demonstrated notable performance over the past 15 years, surpassing market averages with an annualized return of **13.01%**. The company’s market capitalization...
BeOne Medicines, formerly known as BeiGene, has entered into a significant royalty financing agreement, securing an upfront payment of $885 million linked to Amgen’s...